Faron Pharmaceuticals Oy

AIM:FARN Stock Report

Market Cap: UK£156.9m

Faron Pharmaceuticals Oy Valuation

Is FARN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FARN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FARN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FARN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FARN?

Key metric: As FARN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for FARN. This is calculated by dividing FARN's market cap by their current book value.
What is FARN's PB Ratio?
PB Ratio136.2x
Book€1.38m
Market Cap€187.78m

Price to Book Ratio vs Peers

How does FARN's PB Ratio compare to its peers?

The above table shows the PB ratio for FARN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7x
AVCT Avacta Group
3.5x-3.4%UK£168.3m
BVXP Bioventix
16.4xn/aUK£197.0m
PRTC PureTech Health
1.6x-13.0%UK£387.9m
OXB Oxford Biomedica
6.6x93.2%UK£434.6m
FARN Faron Pharmaceuticals Oy
136.2x17.3%UK£156.9m

Price-To-Book vs Peers: FARN is expensive based on its Price-To-Book Ratio (136.2x) compared to the peer average (7x).

Price to Book Ratio vs Industry

How does FARN's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.40m
VAL ValiRx
0.6xn/aUS$2.81m
No more companies available in this PB range
FARN 136.2xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: FARN is expensive based on its Price-To-Book Ratio (136.2x) compared to the UK Biotechs industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is FARN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FARN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio136.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate FARN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

hVIVO

UK£161.9m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.24

7D

-20.1%

1Y

31.3%

Regeneron Pharmaceuticals

US$82.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$741.73

7D

-9.3%

1Y

-6.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€61.60

7D

-5.5%

1Y

17.9%